415 related articles for article (PubMed ID: 9317196)
41. Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate.
McDonagh KT; Dover GJ; Donahue RE; Nathan DG; Agricola B; Byrne E; Nienhuis AW
Exp Hematol; 1992 Nov; 20(10):1156-64. PubMed ID: 1385194
[TBL] [Abstract][Full Text] [Related]
42. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis.
Letvin NL; Linch DC; Beardsley GP; McIntyre KW; Miller BA; Nathan DG
J Clin Invest; 1985 Jun; 75(6):1999-2005. PubMed ID: 2409112
[TBL] [Abstract][Full Text] [Related]
43. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
44. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
Al-Jam'a AH; Al-Dabbous IA
Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
[TBL] [Abstract][Full Text] [Related]
45. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM
Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
[TBL] [Abstract][Full Text] [Related]
46. Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype.
Bandeira IC; Rocha LB; Barbosa MC; Elias DB; Querioz JA; Freitas MV; Gonçalves RP
Cytokine; 2014 Feb; 65(2):217-21. PubMed ID: 24290434
[TBL] [Abstract][Full Text] [Related]
47. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Green NS; Barral S
Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
[TBL] [Abstract][Full Text] [Related]
48. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
[TBL] [Abstract][Full Text] [Related]
49. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
50. Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia.
Hines P; Dover GJ; Resar LM
Pediatr Blood Cancer; 2008 Feb; 50(2):357-9. PubMed ID: 17253639
[TBL] [Abstract][Full Text] [Related]
51. Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.
Lapouméroulie C; Benkerrou M; Odièvre MH; Ducrocq R; Brun M; Elion J
Haematologica; 2005 Mar; 90(3):401-3. PubMed ID: 15749673
[TBL] [Abstract][Full Text] [Related]
52. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
53. Combined effects of arginine and hydroxyurea on BFU-E derived colony growth and HbF synthesis in erythroid progenitors isolated from sickle cell blood.
Baliga BS; Haynes J; Obiako B; Mishra N
Cell Mol Biol (Noisy-le-grand); 2010 Jun; 56 Suppl():OL1290-8. PubMed ID: 20937216
[TBL] [Abstract][Full Text] [Related]
54. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
55. Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness.
Zhu X; Hu T; Ho MH; Wang Y; Yu M; Patel N; Pi W; Choi JH; Xu H; Ganapathy V; Kutlar F; Kutlar A; Tuan D
Haematologica; 2017 Dec; 102(12):1995-2004. PubMed ID: 28971909
[TBL] [Abstract][Full Text] [Related]
56. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: implications for pharmacological intervention.
Marcus SJ; Ware RE
J Pediatr Hematol Oncol; 1999; 21(5):407-11. PubMed ID: 10524455
[TBL] [Abstract][Full Text] [Related]
57. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
58. The Genetic and Clinical Significance of Fetal Hemoglobin Expression in Sickle Cell Disease.
Adekile A
Med Princ Pract; 2021; 30(3):201-211. PubMed ID: 32892201
[TBL] [Abstract][Full Text] [Related]
59. 5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease.
Dover GJ; Charache SH; Boyer SH; Talbot CC; Smith KD
Prog Clin Biol Res; 1983; 134():475-88. PubMed ID: 6198661
[TBL] [Abstract][Full Text] [Related]
60. Genotypic heterogeneity and correlation to intergenic haplotype within high HbF beta-thalassemia intermedia.
Papachatzopoulou A; Kourakli A; Makropoulou P; Kakagianne T; Sgourou A; Papadakis M; Athanassiadou A
Eur J Haematol; 2006 Apr; 76(4):322-30. PubMed ID: 16519704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
